← brief for 2026-09-08 · Slowing decline

Preserved Benefit, Shifting Endpoint: A Systematic Review of SGLT2i in CKD After 65

Key takeaways

A team has registered its plan to pool together past studies of SGLT2 inhibitors in people over 65 with kidney disease. These are diabetes drugs that also slow kidney decline, and the question is whether the benefit holds up in older people. This is only the filed plan, written before the work is done, so there are no results yet.

Who did this work

Marco Ladino · Eliana Bencosme · Eduardo Villa · Marie Sosa

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-07
https://doi.org/10.37766/inplasy2026.9.0030